The AMR Narrative

Facing Antibiotic Resistance in South Africa

My Story: Vanessa Carter

Waking up disfigured in intensive care

My face is disfigured because of a car accident. But a broken health system and over-exposure to antibiotics also played a role.

The accident happened in 2004 when I was 25 years old. I was out for dinner with friends. On our way home our car spun on Republic Road in Johannesburg. It came to a dead stop against a concrete wall. I don’t remember much. But I do recall one of the paramedics asking me if I had medical aid.

I was unable to respond as I was experiencing significant bleeding as well as spinal fluid caused by numerous fractures in my facial bones, as well as injuries to my neck, back, and internal organs. I had been revived at the roadside, but a person informed the emergency services that I lacked insurance and required a transfer to a public facility.

After being unconscious for three days, I woke up in Charlotte Maxeke Johannesburg Academic Hospital. I had an incredible medical team in the high-care ward, but my recovery was extremely difficult.

Damage caused to the car which resulted in numerous injuries

Infection, after infection. When would it end?

After a period of one or two years, I regained the ability to perform everyday tasks such as driving a car and returning to work as my body gradually recovered its physical capabilities. However, I also had to come to terms with the disfigurement of my face and the visual impairments I faced. In order to attain a sense of physical and functional normalcy, I required the insertion of various types of facial prosthetics. Given the complexity of the head area, a sizable medical team was necessary, including specialists like a plastic surgeon, maxillofacial surgeon, Ear Nose and Throat (ENT) surgeon, ophthalmologist, and prosthetist (ocularist), among others. It took me two years, but eventually, I was able to secure medical aid and collaborate with doctors in private practice.

My initial implant was an ocular floor because the bone under my eye socket had smashed to pieces. The second step was to create an artificial eye which we couldn’t quite perfect because the facial bone was asymmetrical. That led to an implant to bridge a wide gap of missing bone between my nose and cheek which couldn’t be restored at the time of my accident.

The surgeon performing the cheek implant was a maxillofacial surgeon. He inserted the implant slightly too high and cut under the lower eyelid. The cut caused scarred tissue to attach itself onto the cheek prosthetic and pull the eyelid skin down and lid outwards. In medical terms, this is called an ectropion, and it was bad news because it exposed me to bacteria which put my other prosthetics at risk of becoming infected.

To fix the ectropion, I needed a plastic surgeon to release the scarred tissue and perform a skin flap.

Two weeks following that flap surgery, I was out shopping and felt moisture on my face. When I reached my car, I pulled down the rear-view mirror and saw pus seeping out of the surgical wound. I called the plastic surgeon’s office in a panic! I was admitted to hospital. Surgery was performed to repair the tissue damage and clean the prosthetic.

Two weeks later, the infection came back again, but this time it was worse.

We performed the procedure again. Two weeks later it happened again!

Tissue damage caused by MRSA after multiple surgeries

 

Doctors saying “this and that” until a test rang alarm bells

I sought answers from several specialists who gave differing opinions. There was little communication between them. In between these consultations and surgeries, I was repeatedly prescribed antibiotics by some of them, often 14-day courses, while I waited to see the next specialist for his opinion.

Eleven months down the line of repeated surgeries and antibiotics, my plastic surgeon insisted the cheek prosthetic be removed.

I argued because the other doctors weren’t echoing that sentiment. I was due for my second sinus drainage surgery, and he was working in the same hospital as the ENT surgeon. The plastic surgeon said, “I am going to come into theatre and if I see that infection is still on that implant, I am taking it out.” I took him with a pinch of salt because I hadn’t signed any indemnity form to approve this. But lo and behold when I woke up the prosthetic was out.

This was the moment that alarm bells rang. I knew the prosthetic had been sent for testing and so decided to call Lancet Laboratories to ask for a copy. I couldn’t understand why my plastic surgeon had taken a risk like this.

Lancet emailed me the test results which made no sense to me with a bunch of “R’s” and “S’s” running down the page. Later, I learned that meant I was either “Resistant” or “Susceptible” to a certain type of antibiotic. A suspicious term at the top of the test also read, “MRSA”.

Pathology test listing antibiotics the bacteria were resistant to

Empowering myself with information as a patient to gain direction

I did as most patients do when they lack information and googled “MRSA” to investigate what that meant. Up came “Methicillin-resistant Staphylococcus aureus” accompanied by the term “antibiotic resistance”. I had never heard either of these terms in my life.

Antibiotic resistance clearly was something I needed to be paying more attention to since I had been taking so many courses of antibiotics and in some instances quitting halfway because they seemed to not be working. I was flabbergasted that “antibiotic resistance” was not common knowledge to me, especially as someone with so many prosthetics in my face and a long-term medical condition that put me at high risk of bacterial infection.

I questioned why I was not told to ask for a test sooner when the antibiotics weren’t responding. Had I known more it would have helped me with the decisions that ultimately led to me having a section of my face amputated.

I had to wait out the infection for a year before doctors could attempt any more surgeries. I was put onto a course of vancomycin for seven days. This is a type of “last-resort” antibiotic used to treat resistant MRSA infections.

Methicillin and penicillin were the types of antibiotics the MRSA bacteria were resistant to, which was why we needed something different. Unfortunately, “last-resort” antibiotics can also be more toxic.

While I was recovering, I managed to find a craniofacial surgeon in the US called Dr Edward J. Caterson who had written an article in a medical journal about face transplants and infection management. His secretary wrote to me and to my surprise said that Caterson was willing to speak to me because he saw cases like mine often. I had compiled my medical history into a few pages which I emailed him. He explained that I needed as few foreign objects and I should have a zygomatic osteotomy and then simple touch-up plastic surgery with the soft tissue. A zygomatic osteotomy meant we needed to cut the bone and realign it.



Fighting against another infection in the bone

I visited numerous renowned doctors in Johannesburg until finding Professor Johan P. Reyneke who was a maxillofacial surgeon. His advice mimicked Dr Caterson’s. We performed the zygomatic osteotomy, and regrettably the infection did reappear. I suspect it could have been worse if we used more foreign prosthetics. Test results showed I had both an infection and allergy. I was using an antibacterial ointment, chloramphenicol (branded as Chloramex), on my surgical wound at the time. We stopped this. Then we also rotated the oral antibiotics from one type to the next for three months.

Reyneke’ s fear was that I had developed a bone infection so we didn’t want to take any chances. One of the most important things that he did was to spend a few minutes explaining how to take my antibiotics more precisely. Timing was of the essence. His words were, “If your antibiotic is due at 5am, I want you to wake up and take it at 5am. Don’t give the bacteria a 20-minute window to mutate. Make sure you take the antibiotic at equal intervals.”

One of the other things I had to master was washing my hands and sanitising them every few minutes, especially when I was out and about. Clean hands were critical, especially since it was a natural habit to touch my face like most other people do, and that was where the deadly infection was.

Clean hands also meant I reduced the risk of spreading the MRSA bacteria to my family, friends, and community. This was equally important in hospital for other patients and medical staff when I was admitted with an infection.

 

Both an allergy and infection in the bone (Osteomyelitis)

Finally seeing the light at the end of the tunnel

 

After a while, the infection began to diminish, allowing me to reveal my face. I have grown cautious of undergoing surgery unless absolutely necessary and am equally wary of relying on antibiotics unless absolutely essential. In terms of antibiotics, I now comprehend that they are not always a universal remedy and deserve my utmost respect.

A significant portion of the past 18 years has been devoted to recovering from life-threatening infections and surgeries that altered my appearance. Over the past decade, I have not only advocated for improved communication regarding antibiotic resistance but also emphasised the importance of patient and public involvement in addressing this issue. Throughout my journey to comprehend antibiotic resistance, I realised there was much more I could have done, but like many others who were uninformed, I was defenseless until I experienced it myself.

Insufficient efforts are being made to alter policies that could profoundly impact the number of lives saved. Antibiotic resistance poses a grave threat to human and animal health. This is not a recently emerging problem that we should merely monitor; it has been neglected for years. We must treat it as a serious matter that permeates nearly every facet of modern medicine. Antibiotic resistance represents a crisis that demands personal engagement from all of us.

Final result after a decade of facial surgeries

Disclaimer: This story is shared with the permission of the individual(s) involved and is intended for educational and awareness purposes only. It does not represent medical advice and should not be used as a substitute for consultation with qualified healthcare professionals. While we encourage you to share the story in its original format, all rights are reserved by The AMR Narrative. Please do not reproduce, modify, or use any part of this story without prior written consent from The AMR Narrative. To request permission, please contact us here.

Share your story to make an impact on AMR

Contact form from contact 7

Cameron Prior

Cameron Prior

BVSc MSc PgCert CertAVP DipECVIM-CA MRCVS

RCVS Recognised Specialist in Small Animal Medicine

Cameron is a European Diplomate in Small Animal Internal Medicine. Passionate about fungal disease, antimicrobial stewardship, endocrinopathy, and facilitating multiple studies to enhance the evidence base of veterinary medicine. Keen to build collaborative projects with colleagues across Europe and to promote clinical research in practice.

Abi Mc Alester

Abi Mc Alester

I am a graduate from the National University of Galway with an Honours BSc in Pharmacology, and a recent graduate from Maynooth University with a MSc in Immunology & Global Health. Throughout university, I was an active member of the Global Health Network, which was a student-led group focusing on health, equity, and international development. Here is where I became interested in the global impact of AMR and the multiple factors that influence its spread. I chose to focus my studies on the mechanisms behind resistance and vaccination design; however, I understand that in order to have a global impact, there needs to be global awareness.

The AMR Narrative provides lived experiences and stories from those affected by resistance, something I believe is so important and why I wanted to help share these stories on social media. Translating scientific knowledge into digestible and understandable language is critical for fighting resistance.

Nduta Kamere

Nduta is a global health pharmacist and AMR consultant recognised for her leadership in antimicrobial stewardship, One Health, and healthcare equity. She has shaped AMR strategies and advanced healthcare accessibility across Africa, with a significant portfolio that includes contributions to the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programmes. As Technical Lead, she oversaw the co-development of the Quadripartite Antimicrobial Resistance Toolkit for Youth Engagement, now used globally to drive advocacy and behaviour change.

Her expertise spans supply chains, pricing, and substandard and falsified medicines, and her research is published in the WHO Bulletin and peer-reviewed journals, informing regional and global AMR policy and practice.

Dr Marie-Anne Bouldouyre

Dr Marie-Anne Bouldouyre is an infectious diseases physician and hospital practitioner in Paris. Twelve years of clinical work in a suburban hospital shaped her understanding of access to care, patient relationships, and the daily reality of antimicrobial resistance.

Since 2022, she has led the Regional Antibiotic Stewardship Centre in Île-de-France and coordinates the national network, working with a multidisciplinary team to promote responsible antibiotic use and strengthen collaboration among healthcare professionals. She also continues to manage complex infections at Saint-Louis Hospital.

Convinced that antimicrobial resistance cannot be tackled by healthcare workers alone, she advocates for the active involvement of patients : understanding, questioning, and taking part in decisions about antibiotics. Their stories are essential to making this issue visible and concrete.

She is proud to collaborate with initiatives such as The AMR Narrative and hopes to foster similar projects in France to give patients a voice in this shared fight.

Dr Erva Cinar

Dr Erva Cinar is a London based paediatric resident doctor and clinical researcher with interest in infectious diseases.

She is currently completing a Master’s in Public Health at the London School of Hygiene & Tropical Medicine. Through the World Medical Association’s Junior Doctor’s Network (WMA-JDN) AMR Working Group, she engages in policy and advocacy on antimicrobial resistance and stewardship at global level.

Alongside her clinical and academic roles, she works with the Royal College of Paediatrics and Child Health (RCPCH) and the International Child Health Group (ICHG); leads on organising teaching resources and educational events to improve research skills for UK paediatric trainees and for global child health professionals.

Hamu Madzedze

Hamu Madzedze is a seasoned Zimbabwean journalist with over 15 years’ experience.

She previously worked for the Zimbabwe Broadcasting Corporation as a reporter and sub-editor, before establishing an independent website, 365HealthDiaries, which focuses on health and gender issues.

She holds a BA in Media Studies and a BA (Special Honours) in Communication and Media from the Zimbabwe Open University, as well as a diploma from the Christian College of Southern Africa.

Her work has been recognised with several awards, including the Global AMR Special Mention Award (2024), the Sexual Health Rights and Equity Fellowship Special Mention Award (2025), and the Merck Foundation Award (2024) for outstanding coverage of health issues, gender, infertility, and genital mutilation, where she achieved third position in the Online Category.

Hamu is passionate about addressing AMR through the media.

Jomana F. Musmar

Dr. Jomana Musmar is a distinguished global policy expert and proactive leader with over fifteen years of government experience in strategic planning, operational design, and policy execution. Renowned for simplifying complex topics with expertise and diplomacy, she has spearheaded innovative solutions to global health challenges, shaped impactful policies, and advanced national and international missions.

As the Executive Director of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, she established and led the council’s operations, liaising with over 600 experts, worldwide, across government, industry, and academia. Her efforts culminated in the development of critical recommendations addressing antimicrobial resistance and interrelated One Health issues, influencing both domestic and global health strategies.

In her tenure as Deputy Director of Strategic Initiatives for the Office of Infectious Diseases and HIV/AIDS Policy, at the US Department of Health and Human Services, Dr. Musmar oversaw the formulation and implementation of national health strategies for vaccines and a range of infectious diseases including HIV/AIDS and viral hepatitis. Her leadership and technical expertise facilitated groundbreaking policies during national emergencies, including responses to the COVID-19 pandemic, and initiatives to combat congenital syphilis and childhood vaccination disruptions. Dr. Musmar holds a Ph.D. in Biodefense from George Mason University, a Master’s degree in Biomedical Science policy and Advocacy from Georgetown University, and is a Lean Six Sigma Black Belt. Fluent in English and Arabic, she is a sought-after speaker and advisor, having represented the United States at premier global health conferences.

Her published works on antimicrobial resistance, pandemic preparedness, and national health security underscore her reputation as a thought leader and innovator in public health and biodefense.

Chris Shaffer

Chris Shaffer was a music, special education teacher, and high school principal for 45 years. At the end of his educational career, he was thrust into the world of AMR infections when a number of abdominal surgeries left him with an E-coli infection which failed to respond to antibiotics. After doctors in the USA left him with little hope for a cure, diminishing health, and a bleak prognosis, he set out on his own.

Chris found success in phage therapy at the Eliava Phage Therapy Center in Tbilisi, Georgia. With phage therapy giving Chris his life back, he has dedicated his retirement years to advocating for and helping raise awareness of phage therapy used for AMR infections. He tells the story of his phage journey in a book titled, Finding Phage: How I Partnered with a Friendly Virus to Cure My Deadly Bacterial Superinfection. His website, phagetherpyusa.com helps others learn to understand the healing power of phage therapy.

Demi Christofi

Demi is an Associate Scientific Director at a medical communications agency, with a background in microbiology and a longstanding focus on antimicrobial resistance. She holds an MSc in Microbiology, where she first became interested in the global challenge of resistance and the need to bring scientific understanding to wider audiences.

Demi’s career has centred on a simple but powerful belief: that how we communicate science matters. Her work focuses on making complex data clear, engaging, and accessible – whether for healthcare professionals, policy makers, or the patients most affected by infection and resistance. She has contributed to a wide range of AMR-focused projects, including educational programmes, congress communications and stewardship initiatives.

A central thread in Demi’s work is the importance of the patient voice. She is passionate about making sure real-world experiences of treatment failure, recurrent infections, and the anxiety surrounding resistance are not lost in the data. She believes that listening to patients and involving them meaningfully is essential for shaping more effective, human-centred responses to AMR.

Demi is also a strong advocate of the One Health approach, recognising AMR as a complex, interconnected issue that spans human health, animal health, and the environment. She is particularly drawn to efforts that move beyond siloed thinking and focus on practical, joined-up solutions.

In 2025, Demi joined The AMR Narrative as an Independent Advisor, where she supports the charity’s mission to centre communication, community, and inclusion in the global AMR response.

Outside of work, she is a Girlguiding unit leader and a qualified yoga teacher. These roles reflect her commitment to care, learning, and creating supportive spaces for others.

Andrea Hartley

Andrea has worked in health communications and campaigning for 3 decades. She is committed to fighting AMR through timely and appropriate communications globally,.

Andrea set up Skating Panda, the creative social and environmental impact consultancy, over a decade ago and drives its impact and growth. Focused on original and lasting public interest communications as well as issue strategy and advocacy, the Panda team has a track record of prompting tipping points in the status quo that drive better social and planetary outcomes.

Andrea’s combination of commercial marketing and development experience with deep issue knowledge have been sought by decision-makers at global summits, corporate and NGO board members, and have enabled her to set up multi-million fundraising platforms and push through policies that change and save lives. 

Andrea is Vice Chair of mothers2mothers, the world’s largest employer of women living with HIV, and a Board Director of Maymessy, a food poverty social enterprise.

A lifelong advocate for gender equality, she played a key role in establishing the UK’s Women’s Equality Party.

Esmita Charani

Professor Esmita Charani is a pharmacist and researcher investigating how we use antibiotics in different cultural and social contexts. She works with teams in the UK, India, and South Africa to develop research programmes investigating all aspects of antimicrobial resistance in human populations with a focus in hospital settings.

She has experience in communicating her research with patients and the public through various media including animations, blogs, and educational videos.